Clinical Trials Logo

Filter by:
NCT ID: NCT00047112 Completed - Esophageal Cancer Clinical Trials

Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer

Start date: May 2002
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy with radiation therapy before surgery may shrink the tumor so it can be removed during surgery. It is not yet known if surgery is more effective with or without radiation therapy and chemotherapy in treating esophageal cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without radiation therapy and chemotherapy in treating patients who have esophageal cancer.

NCT ID: NCT00046228 Completed - Clinical trials for Myocardial Infarction

A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)

Start date: August 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood flowing past the clot), is safe and effective in the treatment of heart attacks compared to only abciximab given during coronary intervention.

NCT ID: NCT00046150 Completed - Diabetes, Type I Clinical Trials

12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes.

Start date: May 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the safety of HMR 1964 and insulin aspart when used in external pumps with respect to catheter occlusions, GHb assessment, insulin doses, blood glucose parameters, hypoglycemic episodes, unexplained hyperglycemia, adverse events, laboratory data, and vital signs.

NCT ID: NCT00045760 Completed - Sepsis Clinical Trials

The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis

Start date: September 2002
Phase: Phase 4
Study type: Interventional

Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction. It usually results from bacterial infections, but it may occur in response to other pathogens, such as fungi, viruses, and parasites.

NCT ID: NCT00044915 Completed - Stroke Clinical Trials

Repinotan in Patients With Acute Ischemic Stroke

Start date: December 2000
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke. At study entry patients will be randomized to Repinotan HCl or placebo in a 1:1 ratio. The total treatment period wil be 72 hours.

NCT ID: NCT00044564 Completed - Clinical trials for Carcinoma, Renal Cell

Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

Start date: December 2001
Phase: Phase 2
Study type: Interventional

In patients with renal cell cancer, most frequent methods of treatment include surgery, chemotherapy, hormonal therapy, and immunotherapy. Renal cell carcinoma is usually considered to be radioresistant and chemoresistant. In patients with metastatic disease, the options are limited. The taxanes are among the most commonly used class of chemotherapy agents in clinical oncology today but they are not effective in renal cancers; the development of Bay 59-8862 targets taxane-resistant tumors and the current protocol is designed to test the safety and efficacy of Bay 59-8862 in patients with advanced renal cell carcinoma.

NCT ID: NCT00044551 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

Start date: February 2002
Phase: Phase 2
Study type: Interventional

Almost two-thirds of lymphoma cases are Non-Hodgkin's Lymphomas (NHL). NHL is a malignant process that affects lymphoid cells found both in the lymph nodes and extranodally. Incidence and mortality rates from NHL are highest in developed countries. While many patients with aggressive NHL are curable with initial anthracycline-containing regimens, the majority of patients will relapse or prove refractory to initial therapy. The prognosis of patients with disease recurrence following a multidrug regimen is also limited. The current protocol is designed to test the safety and efficacy of BAY 59-8862 in patients with Aggressive Refractory Non-Hodgkin's Lymphoma.

NCT ID: NCT00044421 Completed - Diabetes Mellitus Clinical Trials

Treatment of Peripheral Neuropathy in Patients With Diabetes

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.

NCT ID: NCT00044408 Completed - Clinical trials for Diabetic Neuropathies

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of this protocol is to determine if an investigational drug known as LY333531 is effective in treating nerve malfunction in diabetes.

NCT ID: NCT00044278 Completed - Epilepsy Clinical Trials

Pediatric Epilepsy Study in Subjects 1-24 Months

Start date: September 2000
Phase: Phase 2
Study type: Interventional

This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's current epilepsy medications.